Arcus Biosciences (RCUS) Q2 2024 earnings summary

Executive summary

• Advancing a robust late-stage oncology pipeline with multiple Phase 3 studies in lung, GI, renal, and pancreatic cancers, including domvanalimab, casdatifan, quemliclustat, and etrumadenant.

• Completed enrollment for STAR-221 Phase 3 trial in upper GI cancers; Taiho exercised its option for quemliclustat, triggering opt-in and milestone payments.

• Strategic collaborations with Gilead, Taiho, AstraZeneca, and Exelixis provide funding, resources, and global reach.

• Strong financial position with $1.0 billion in cash and investments as of June 30, 2024, supporting operations into 2027.

• Multiple pivotal data readouts and new Phase 3 study initiations expected in late 2024 and 2025.

Financial highlights

• Q2 2024 revenue was $39 million, up 34% year-over-year, with a $107 million cumulative catch-up from a Gilead contract amendment recognized in 2024.

• R&D expenses rose to $115 million in Q2 2024, reflecting higher late-stage clinical activity; G&A expenses were $30 million.

• Net loss for Q2 2024 was $93 million ($1.02/share), compared to $75 million ($1.04/share) in Q2 2023.

• Cash, cash equivalents, and marketable securities totaled $1.0 billion as of June 30, 2024.

• Year-end 2024 cash/investments guidance: $885–$925 million, funding operations into 2027.

Outlook and guidance

• Cash runway expected to fund operations into 2027; year-end 2024 cash balance projected between $885 million and $925 million.

• Expect to recognize ~$30 million in GAAP revenue per quarter for the rest of 2024.

• Data from key studies (domvanalimab, casdatifan, quemliclustat) expected in late 2024 and 2025; new Phase 3 trials (PEAK-1, PRISM-1) planned for 2025.

• R&D expenses to see modest increases through 2024, then level off as focus shifts from Dom to CAS and Quemly.

• No product sales expected in the near term; revenue will continue to be driven by collaboration and milestone payments.